LIVZON PHARMA (01513) announced that the company and its subsidiaries plan to utilize idle自有资金 not exceeding 2.5 billion yuan to purchase委托理财产品. Within the authorized quota, the funds can be used on a rolling basis. The total investment amount used to purchase financial products at any given time, including amounts reinvested from the proceeds of prior investments, shall not exceed the stated quota.